Advances in Macular Telangiectasia Type 2 Treatment with Encelto Implant

Overview

Macular telangiectasia type 2 (MacTel) previously lacked treatments to slow disease progression until the FDA approval of Encelto (revakinagene taroretcel-lwey). Encelto is a novel encapsulated cell therapy implant that delivers sustained ciliary neurotrophic factor (CNTF) to preserve photoreceptors and slow vision loss. Clinical data demonstrate its long-term efficacy and a favorable safety profile.

Background

Macular telangiectasia type 2 is a progressive retinal disease characterized by photoreceptor loss leading to vision decline. Prior to Encelto, treatment options were limited to managing late-stage complications such as choroidal neovascular membranes with anti-VEGF agents, without affecting the underlying disease progression. Various off-label treatments including steroids, laser therapy, and acetazolamide failed to slow progression. Encelto represents an innovative approach by delivering neurotrophic support directly to the retina via a surgical implant.

Data Highlights

Clinical trials including two phase 3 studies and a well-powered phase 2 study demonstrated that Encelto slows photoreceptor loss, reduces decline in reading speed, and preserves retinal sensitivity measured by microperimetry. The implant remains effective for at least 10 years. Adverse events are primarily related to the surgical procedure, such as conjunctival erosion and implant prolapse, and can be minimized with proper technique.

Key Findings

• Before Encelto, no treatments slowed MacTel progression; only late complications were managed.
• Encelto is an encapsulated cell implant releasing recombinant human CNTF to protect photoreceptors.
• The implant is surgically placed in the vitreous cavity and remains effective for at least a decade.
• Clinical trials show Encelto slows photoreceptor loss, preserves reading speed, and maintains retinal sensitivity.
• Adverse events mainly relate to surgical implantation and can be mitigated with proper technique.
• Patient education focuses on setting realistic expectations about slowing vision loss rather than improvement.

Clinical Implications

Encelto offers a new therapeutic option for MacTel patients aiming to slow disease progression and preserve vision. Retina specialists should familiarize themselves with the surgical implantation technique to minimize complications. Clear communication with patients about the goal of slowing vision loss is essential to support informed decision-making.

Conclusion

Encelto represents a significant advance in MacTel care by providing a long-term, disease-modifying treatment option where none previously existed. Its favorable risk-benefit profile and sustained efficacy position it as an important tool in managing this challenging condition.

References

1. Bakri SJ, Goldberg RA, Retinal Physician, 2024 -- Peer Perspectives: Advances in Macular Telangiectasia Type 2 Care